Zhu, Dantong
Arnold, Matt
Samuelson, Brady A.
Wu, Judy Z.
Mueller, Amber
Sinclair, David A.
Kane, Alice E.
Funding for this research was provided by:
National Institute on Aging (R01AG019719, R00AG070102)
Article History
Received: 31 July 2024
Accepted: 22 October 2024
First Online: 31 October 2024
Declarations
:
: All animal experiments were approved by the Institutional Animal Care and Use Committee of the Harvard Medical Area.
: Not applicable.
: D.A.S. is a founder, equity owner, advisor to, director of, board member of, consultant to, investor in and/or inventor on patents licensed to Revere Biosensors, UpRNA, GlaxoSmithKline, Wellomics, DaVinci Logic, InsideTracker (Segterra), Caudalie, Animal Biosciences, Longwood Fund, Catalio Capital Management, Frontier Acquisition Corporation, AFAR (American Federation for Aging Research), Life Extension Advocacy Foundation (LEAF), Cohbar, Galilei, EMD Millipore, Zymo Research, Immetas, Bayer Crop Science, EdenRoc Sciences (and affiliates Arc-Bio, Dovetail Genomics, Claret Bioscience, MetroBiotech, Astrea, Liberty Biosecurity and Delavie), Life Biosciences, Alterity, ATAI Life Sciences, Levels Health, Tally (aka Longevity Sciences) and Bold Capital. D.A.S. is an inventor on a patent application filed by Mayo Clinic and Harvard Medical School that has been licensed to Elysium Health. Additional info on D.A.S. affiliations can be found at . After contributing to this work, A.M assumed a role as scientific editor for Cell Metabolism, Cell Press. The other authors declare no competing interests.